TP53 and cancer: The current study evaluates temporal (determined by time interval between tissue DNA and blood‐derived ctDNA), cancer histopathology‐related (examining colorectal vs noncolorectal cancer), spatial (determined by tissue extracted from primary vs metastatic site), and quantitative (reflected by %ctDNA) effects on TP53 alteration concordance among 433 patients who underwent blood‐derived ctDNA and tissue biopsy tests.